Phraction Management’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-3,310
Closed -$336K 65
2022
Q2
$336K Buy
+3,310
New +$361K 0.22% 54

Other funds holding BSX.PRA

Phraction Management's BSX.PRA Position: Q3 2022 in Review

Phraction Management sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q3 2022, closing a stake of 3,310 shares — an estimated $336K sold.

Phraction Management first reported a position in BSX.PRA in Q2 2022 and held it in 1 quarter. The position peaked at $336K in Q2 2022. 54 funds tracked by Wall St. Rank hold BSX.PRA as of Q3 2022.

  • Phraction Management reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q3 2022 after selling out during the quarter.
  • Phraction Management sold 3,310 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q3 2022, an estimated $336K.
  • Phraction Management first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q2 2022 and held it in 1 quarter.
  • Phraction Management's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $336K in Q2 2022.
  • 54 funds tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q3 2022.

Based on Phraction Management's 13F filing for Q3 2022, filed 2 Nov 2022.